David Stack - Chairman and Chief Executive Officer
David Stack co-founded Pacira Pharmaceuticals in and served as the Chairman and Chief Executive Officer of that company until its merger with DepoTech Corporation in 2010, at which time he became the Chairman and CEO of the newly combined company, Pacira Biosciences, Inc.
Charles A. Reinhart, III - President and Chief Operating Officer
Charles Reinhart has more than 20 years of experience in the healthcare industry, including serving as the Executive Vice President and Chief Commercial Officer at Cempra, Inc., a biopharmaceutical company that developed treatments for infectious diseases.
Scott Braunstein, MD - Chief Medical Officer
Dr. Scott Braunstein previously served as a Global Clinical Development Leader in the Cardiovascular and Gastrointestinal Business Unit at Johnson & Johnson, and as Executive Vice President and Chief Medical Officer at Heartflow, Inc.
Christie Cunningham - General Counsel and Secretary
Christie Cunningham has over 20 years of legal experience with a focus on healthcare and life science industries. Prior to joining Pacira, she served as the General Counsel and Corporate Secretary at Clinigen Group.
Srinivas Rao - Chief Financial Officer
Srinivas Rao has more than 20 years of finance and accounting experience in the biopharmaceutical industry. Prior to joining Pacira, he served as the Chief Financial Officer of Zynerba Pharmaceuticals.
Laurence E. Paul, Ph.D. - Director
Dr. Laurence E. Paul has over 40 years of experience in the pharmaceutical and biotechnology industry, including serving as the Director of Cardiovascular Pharmacology at Merck.
Gary F. Pace, Ph.D. - Lead Independent Director
Dr. Gary F. Pace has over 35 years of experience in the pharmaceutical and biotechnology industry, including serving as the Co-Founder and Chief Executive Officer of Auven Therapeutics Management, LLC.
Pacira Biosciences inc currently has 829 employees.
News about Pacira Biosciences inc Key Personnel |
Pacira BioSciences: A Strategic Move Towards Strengthening Shareholder Value Amidst ChallengesIn a rapidly evolving biopharmaceutical landscape, Pacira BioSciences, Inc. (Nasdaq: PCRX) has made significant strides to enhance its value for shareholders. Recently, the company announced a $300 million aggregate share repurchase authorization, reiterating its confidence in its 5x30 plan, a strategic framework aimed at driving sustainable growth and profitability.Despite facing some financial hurdles, including a cumulative net loss of $100 million within the 12 months ending in the fourth quarter of 2024, Pacira’s management remains optimistic about the company s potential. The recorded negative return on inv...
|
In a strategic move signaling its commitment to innovation and growth, Pacira Biosciences has announced new five-year objectives designed to expedite its transformation into a leading biopharmaceutical entity. With a robust preliminary unaudited revenue projection for 2024 at $701.0 million, the company is poised to leverage this financial momentum to enhance its research and development capabilities, particularly in the realm of pain management and chronic illness treatment.At the recent ACR Convergence annual meeting, Pacira debuted findings centered around PCRX-201, its investigational product aimed at addressing moderate to severe osteoarthritis of the knee—one of the most prevalent degenerative joint ...
|
TAMPA, Fla. Sept. 09, 2024 - Pacira BioSciences, Inc. a leading player dedicated to non-opioid pain management and regenerative health solutions, recently announced the provision of inducement awards to 17 new employees on September 4, 2024. These awards were granted under Pacira s Amended and Restated 2014 Inducement Plan with the intention of enticing these employees to join the company. The Compensation Committee of the Board of Directors duly approved these awards in compliance with Nasdaq Listing Rule 5635(c)(4).
Simultaneously, Pacira BioSciences Inc s stock has witnessed a commendable gain of 7.96% over the past five trading days. Moreover, the company s revenue per employee has displaye...
|
